{"id":62625,"date":"2022-08-10T15:28:13","date_gmt":"2022-08-10T13:28:13","guid":{"rendered":"https:\/\/cri1149.mlcom-dev.net\/?post_type=publications&#038;p=62625"},"modified":"2025-09-11T16:47:59","modified_gmt":"2025-09-11T14:47:59","slug":"a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma","status":"publish","type":"publication","link":"https:\/\/cri1149.mlcom-dev.net\/en\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/","title":{"rendered":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-62625","publication","type-publication","status-publish","hentry"],"acf":{"numero_de_publication":"[:fr]Annals of Oncology.[:]","date_de_publication":"20201111","numero_doi":"","equipe":[237],"auteurs-liste":[{"texte_libre":false,"auteur-lien":47152,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]O. Gayet[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]P. Duconseil[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]C. Vanbrugghe[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]J. Roques[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]M. Bigonnet[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Y. Blum[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]N. Elarouci[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]L. Armenoult[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]M. Ayadi[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]A. de Reyni\u00e8s[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]F. Puleo[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]J. Augustin[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]J.F. Emile[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]M. Svrcek[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]T. Arsenijevic[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]P. Hammel[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]M. Giovannini[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]P. Grandval[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]L. Dahan[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]V. Moutardier[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]M. Gilabert[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]J.L. Van Laethem[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]J.B. Bachet[:]"},{"texte_libre":false,"auteur-lien":13055,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]J. Iovanna[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]N.J. Dusetti[:]"}],"auteurs-manuel":"","liens_externes":null,"liens":[{"lien":"https:\/\/pubmed.ncbi.nlm.nih.gov\/33188873\/"}],"paragraphe":"[:fr]<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Background:\u00a0<\/strong>Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Patients and methods:\u00a0<\/strong>Concomitant chemosensitivity and genome-wide RNA profiles were carried out on preclinical models (primary cell cultures and patient-derived xenografts) derived from patients with PDAC included in the PaCaOmics program (<a title=\"See in ClinicalTrials.gov\" href=\"http:\/\/clinicaltrials.gov\/show\/NCT01692873\">NCT01692873<\/a>). The RNA-based stratification was tested in a monocentric cohort and validated in a multicentric cohort, both retrospectively collected from resected PDAC samples (67 and 368 patients, respectively). Forty-three (65%) and 203 (55%) patients received adjuvant gemcitabine in the monocentric and the multicentric cohorts, respectively. The relationships between predicted gemcitabine sensitivity and patients' overall survival (OS) and disease-free survival were investigated.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Results:\u00a0<\/strong>The GemPred RNA signature was derived from preclinical models, defining gemcitabine sensitive PDAC as GemPred+. Among the patients who received gemcitabine in the test and validation cohorts, the GemPred+ patients had a higher OS than GemPred- (P = 0.046 and P = 0.00216). In both cohorts, the GemPred stratification was not associated with OS among patients who did not receive gemcitabine. Among gemcitabine-treated patients, GemPred+ patients had significantly higher OS than the GemPred-: 91.3 months [95% confidence interval (CI): 61.2-not reached] versus 33 months (95% CI: 24-35.2); hazard ratio 0.403 (95% CI: 0.221-0.735, P = 0.00216). The interaction test for gemcitabine and GemPred+ stratification was significant (P = 0.0245). Multivariate analysis in the gemcitabine-treated population retained an independent predictive value.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Conclusion:\u00a0<\/strong>The RNA-based GemPred stratification predicts the benefit of adjuvant gemcitabine in PDAC patients.<\/p>\r\n<\/div>[:]","paragraphe_en":"[:fr]<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Background:\u00a0<\/strong>Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Patients and methods:\u00a0<\/strong>Concomitant chemosensitivity and genome-wide RNA profiles were carried out on preclinical models (primary cell cultures and patient-derived xenografts) derived from patients with PDAC included in the PaCaOmics program (<a title=\"See in ClinicalTrials.gov\" href=\"http:\/\/clinicaltrials.gov\/show\/NCT01692873\">NCT01692873<\/a>). The RNA-based stratification was tested in a monocentric cohort and validated in a multicentric cohort, both retrospectively collected from resected PDAC samples (67 and 368 patients, respectively). Forty-three (65%) and 203 (55%) patients received adjuvant gemcitabine in the monocentric and the multicentric cohorts, respectively. The relationships between predicted gemcitabine sensitivity and patients' overall survival (OS) and disease-free survival were investigated.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Results:\u00a0<\/strong>The GemPred RNA signature was derived from preclinical models, defining gemcitabine sensitive PDAC as GemPred+. Among the patients who received gemcitabine in the test and validation cohorts, the GemPred+ patients had a higher OS than GemPred- (P = 0.046 and P = 0.00216). In both cohorts, the GemPred stratification was not associated with OS among patients who did not receive gemcitabine. Among gemcitabine-treated patients, GemPred+ patients had significantly higher OS than the GemPred-: 91.3 months [95% confidence interval (CI): 61.2-not reached] versus 33 months (95% CI: 24-35.2); hazard ratio 0.403 (95% CI: 0.221-0.735, P = 0.00216). The interaction test for gemcitabine and GemPred+ stratification was significant (P = 0.0245). Multivariate analysis in the gemcitabine-treated population retained an independent predictive value.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Conclusion:\u00a0<\/strong>The RNA-based GemPred stratification predicts the benefit of adjuvant gemcitabine in PDAC patients.<\/p>\r\n<\/div>[:]","documents":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma - CRI<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma - CRI\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"CRI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-11T14:47:59+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/\",\"name\":\"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma - CRI\",\"isPartOf\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#website\"},\"datePublished\":\"2022-08-10T13:28:13+00:00\",\"dateModified\":\"2025-09-11T14:47:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/cri1149.mlcom-dev.net\/en\/cri-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/cri1149.mlcom-dev.net\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#website\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/\",\"name\":\"CRI - Centre de Recherche sur l'Inflammation\",\"description\":\"Centre de Recherche sur l&#039;Inflammation\",\"publisher\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cri1149.mlcom-dev.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#organization\",\"name\":\"CRI1149\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg\",\"contentUrl\":\"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg\",\"width\":215,\"height\":176,\"caption\":\"CRI1149\"},\"image\":{\"@id\":\"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\",\"https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma - CRI","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma - CRI","og_url":"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/","og_site_name":"CRI","article_publisher":"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","article_modified_time":"2025-09-11T14:47:59+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/","url":"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/","name":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma - CRI","isPartOf":{"@id":"https:\/\/cri1149.mlcom-dev.net\/#website"},"datePublished":"2022-08-10T13:28:13+00:00","dateModified":"2025-09-11T14:47:59+00:00","breadcrumb":{"@id":"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cri1149.mlcom-dev.net\/publication\/a-transcriptomic-signature-to-predict-adjuvant-gemcitabine-sensitivity-in-pancreatic-adenocarcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cri1149.mlcom-dev.net\/en\/cri-home\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/cri1149.mlcom-dev.net\/publications\/"},{"@type":"ListItem","position":3,"name":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma"}]},{"@type":"WebSite","@id":"https:\/\/cri1149.mlcom-dev.net\/#website","url":"https:\/\/cri1149.mlcom-dev.net\/","name":"CRI - Centre de Recherche sur l'Inflammation","description":"Centre de Recherche sur l&#039;Inflammation","publisher":{"@id":"https:\/\/cri1149.mlcom-dev.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cri1149.mlcom-dev.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cri1149.mlcom-dev.net\/#organization","name":"CRI1149","url":"https:\/\/cri1149.mlcom-dev.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/","url":"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","contentUrl":"https:\/\/cri1149.mlcom-dev.net\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","width":215,"height":176,"caption":"CRI1149"},"image":{"@id":"https:\/\/cri1149.mlcom-dev.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/"]}]}},"post_type":"publication","author_name":"","_links":{"self":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/publication\/62625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/types\/publication"}],"acf:term":[{"embeddable":true,"taxonomy":"equipes","href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/equipes\/237"}],"wp:attachment":[{"href":"https:\/\/cri1149.mlcom-dev.net\/en\/wp-json\/wp\/v2\/media?parent=62625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}